NewAmsterdam Pharma Company N.V ($NAMS) Insider Trading & Smart Money Activity
NewAmsterdam Pharma Company N.V. ($NAMS) has 3 insider trades and 1 analyst rating on file. In the last 12 months on the open market, no insider bought and 1 insider sold ($1.26M), net -$1.26M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 1
- Net insider $ (12 mo)
- -$1.26M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 0
- Analyst ratings on file
- 1
NAMS insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q3 2026 | 0 | 1 · $1.26M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All NAMS insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Kastelein Johannes Jacob PieterChief Scientific Officer | Sell (Open-market sale) 10b5-1 | 50.25K sh | $1.26M | -9.0% | — | |||||
| Analyst | RBC Capital | Reiterates to buy | PT $51 | +9.1% | -16.0% | Read | |||||
| Insider | Kooij Louise FrederikaChief Accounting Officer | Sell (Option exercise) | 40K sh | +9.9% | +2.9% | — | |||||
| Insider | Kooij Louise FrederikaChief Accounting Officer | Buy (Option exercise) | 40K sh | $451K | +9.9% | +2.9% | — |
1W / 1M / 6M = how NAMS moved from the trade or filing date.
Insider trading in NAMS: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 1 | -$1.26M | Sep 30, 2026 | |
| Kooij Louise Frederika | Chief Accounting Officer | 2 | — | Jun 22, 2026 |
Analyst ratings on NAMS
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| RBC Capital | Reiterates | buy | $51 | +9.1% | -16.0% | Read |
Frequently asked questions
Are NAMS insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 1 insider made 1 open-market sale worth $1.26M, a net -$1.26M.
What is the latest insider trade in NAMS?
Kastelein Johannes Jacob Pieter, Chief Scientific Officer filed a sell (open-market sale) of 50.25K sh worth $1.26M on Sep 30, 2026.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.